Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337320 | 1.00 | P2RY2 (0.42) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4329094 | 1.00 | P2RY2 (0.42) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4260632 | 1.00 | P2RY2 (0.42) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4338692 | 1.00 | P2RY2 (0.42) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4270302 | 0.94 | P2RY2 (0.41) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4338799 | 0.94 | P2RY2 (0.41) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4326577 | 0.94 | P2RY2 (0.41) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4265870 | 0.94 | P2RY2 (0.41) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4319373 | 0.94 | P2RY2 (0.41) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL4268257 | 0.87 | CYP3A4 (0.43) | P2RY2P2RY4POLA1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | claimed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | claimed |
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | ENTPD5, PNP, ENTPD1 | P2RY2 377/4885P2RY4 301/4885POLA1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.